ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AXSM vs ABVX // FREE CASH FLOW YIELD

Axsome Therapeutics Inc. (NASDAQ) VS. Abivax SA (NASDAQ) • 15-METRIC TALLY: AXSM 3 — ABVX 8
▲ FREE CASH FLOW YIELD LEADER: ABVX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. ABVX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AXSM ABVX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -21.90% 9.90% -31.80 ABVX /roic <GO>
EV/EBITDA & P/E Valuation — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -1.25% 2.21% -3.46 ABVX /fcf-yield <GO>
Operating Margin -26.10% 13.90% -40.00 ABVX /operating-margins <GO>
Net Profit Margin -28.70% 10.90% -39.60 ABVX /net-margins <GO>
Revenue Growth (YoY) 65.50% 8.80% +56.70 AXSM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.34 3.74 +1.60 AXSM /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 ABVX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 20.5 38.7 -18.20 ABVX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.15 1.05 +0.10 AXSM /macro-sensitivity <GO>
Forward P/E Multiple 35.0x 30.5x +4.50 ABVX /forward-pe <GO>
Enterprise Scale & Market Cap $7.12B $7.41B -$284.4M ABVX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AXSM REV ABVX REV AXSM GROSS % ABVX GROSS % AXSM FCF ABVX FCF
FY 2025 $638.5M — — — -$93.9M —
FY 2024 $385.7M — — — -$128.7M —
FY 2023 $270.6M — — — -$157.3M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
ABVX // BETA 1.05